Zhejiang Conba Pharmaceutical Co (SHSE:600572) Additional Paid-In Capital : ¥0 Mil(As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Zhejiang Conba Pharmaceutical Co Additional Paid-In Capital?

Zhejiang Conba Pharmaceutical Co's annual additional paid-in capital declined from Dec. 2021 (¥84 Mil) to Dec. 2022 (¥0 Mil) but then stayed the same from Dec. 2022 (¥0 Mil) to Dec. 2023 (¥0 Mil).

Zhejiang Conba Pharmaceutical Co Additional Paid-In Capital Historical Data

The historical data trend for Zhejiang Conba Pharmaceutical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Conba Pharmaceutical Co Additional Paid-In Capital Chart

Zhejiang Conba Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

572.02

571.72

83.85

Zhejiang Conba Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															-	-	-	-	-

Zhejiang Conba Pharmaceutical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Zhejiang Conba Pharmaceutical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Zhejiang Conba Pharmaceutical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Conba Pharmaceutical Co (SHSE:600572) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Conba Pharmaceutical Co Ltd (SHSE:600572) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

N/A

Address

No. 568 Binkang Road, New and High-Technology Development Zone, Binjiang District, Zhejiang, Hangzhou, CHN, 310052

Website

http://www.conba.com.cn

Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.

Executives

Hu Ji Qiang	Director
Yuan Zhen Xian	senior management
Yin Shi Shui	Supervisors
Xu Chun Ling	senior management
Jin Zu Cheng	Directors, senior managers
Ye Jian Feng	Supervisors
Ying Chun Xiao	Director
Chen Ming	Director
Luo Guo Liang	Director
Wu Zhong Shi	Supervisors
Wang Ru Wei	Director
Yang Jun De	senior management
Yang Xian Min	senior management
Chen Yue Zhong	senior management
Li Jian Zhong	Supervisors

Zhejiang Conba Pharmaceutical Co (SHSE:600572) Headlines

No Headlines